Entyvio and Basal cell carcinoma - a phase IV clinical study of FDA data

Summary:

Basal cell carcinoma is reported as a side effect among people who take Entyvio (vedolizumab), especially for people who are male, 60+ old, have been taking the drug for 1 - 2 years also take Rivaroxaban, and have Inflammatory bowel disease.

The phase IV clinical study analyzes which people have Basal cell carcinoma when taking Entyvio. It is created by eHealthMe based on reports of 23,685 people who have side effects when taking Entyvio from the FDA, and is updated regularly.

What is Entyvio?

Entyvio has active ingredients of vedolizumab. It is often used in crohn's disease. eHealthMe is studying from 23,827 Entyvio users. Check the latest studies of Entyvio.

What is Basal cell carcinoma?

Basal cell carcinoma (a skin cancer, it rarely metastasizes or kills) is found to be associated with 1,092 drugs and 1,382 conditions by eHealthMe. Check the latest studies of Basal cell carcinoma.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 03, 2026

23,685 people reported to have side effects when taking Entyvio.
Among them, 60 people (0.25%) have Basal cell carcinoma.

Could Entyvio cause Basal cell carcinoma?

Among these 60 people:

How long have people been on Entyvio when they have Basal cell carcinoma? *

What is the gender of people who have Basal cell carcinoma when taking Entyvio? *

female: 22.81 %
male: 77.19 %

What is the age of people who have Basal cell carcinoma when taking Entyvio? *

What are other drugs people take besides Entyvio? *

Rivaroxaban: 35 people, 58.33%
Metformin: 29 people, 48.33%
Fluorouracil: 28 people, 46.67%
Amlodipine: 28 people, 46.67%
Lansoprazole: 28 people, 46.67%
Losartan: 22 people, 36.67%
Losartan Potassium: 9 people, 15.00%
Metformin Hydrochloride: 7 people, 11.67%
Methotrexate: 4 people, 6.67%
Azathioprine: 4 people, 6.67%

What are other side effects people have besides Basal cell carcinoma? *

Rashes (redness): 35 people, 58.33%
Diarrhea: 3 people, 5.00%
Joint Pain: 3 people, 5.00%
Drug Intolerance (drug sensitivity): 3 people, 5.00%
Drug Ineffective: 3 people, 5.00%
Liver Function Test Abnormal: 3 people, 5.00%
Histone Antibody Positive: 2 people, 3.33%
Fever: 2 people, 3.33%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 2 people, 3.33%
Gastrointestinal Stenosis (narrowing of gastrointestinal tract): 2 people, 3.33%

What are the existing conditions these people have? *

Inflammatory Bowel Disease: 36 people, 60.00%
Cardiac Disorder: 31 people, 51.67%
Transient Ischaemic Attack (a transient episode of neurologic dysfunction caused by ischemia (loss of blood flow)): 30 people, 50.00%
Diabetes: 30 people, 50.00%
Gastrointestinal Disorder (functional problems of gastrointestinal tract): 30 people, 50.00%
High Blood Cholesterol: 30 people, 50.00%
Rickets (softening of bones): 30 people, 50.00%
Rashes (redness): 30 people, 50.00%
Ulcerative Colitis (inflammatory bowel disease (ibd). it causes swelling, ulcerations, and loss of function of the large intestine): 9 people, 15.00%
High Blood Pressure: 2 people, 3.33%

* Approximation only. Some reports may have incomplete information.

Do you take Entyvio and have Basal cell carcinoma?

- Check whether Basal cell carcinoma is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Entyvio:

Entyvio (23,827 reports)

Browse all side effects of Entyvio:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Basal cell carcinoma:

Basal cell carcinoma (1,092 drugs)

Browse all the conditions that are associated with Basal cell carcinoma:

Basal cell carcinoma (1,382 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on vedolizumab (the active ingredients of Entyvio) and Entyvio (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.